Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.

Overview

Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15^th Post-American Society of Hematology (ASH) and the 25^th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9^th -10^th December 2020 and 7^th -10^th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman* and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases. This article is protected by copyright. All rights reserved.